Novel oral extended-release drug approved for Parkinson's disease

FDA approved Crexont, a novel, oral extended-release formulation of carbidopa and levodopa (CD/LD), for the treatment of Parkinson’s disease. According to a manufacturer press release, the drug delivers more “good on” time with less frequent dosing compared with immediate release (IR) CD/LD. Approval was based on the 20-week RISE-PD trial, in which Crexont demonstrated a statistically significant improvement of 0.5 hours of additional “good on” time per day compared with IR CD/LD, with an average of three times daily dosing vs. five times daily dosing with IR CD/LD.